Key result
This review discusses the diagnosis, treatment, and prevention of coronary artery disease in patients with chronic kidney disease, highlighting the exclusion of advanced CKD patients from most trials.
Why the study?
Evaluating CAD in CKD is challenging due to altered diagnostic test performance, and the effectiveness and safety of interventions remain uncertain because trials often exclude advanced CKD.
What are the challenges and strategies in the diagnosis, treatment, and prevention of coronary artery disease in patients with chronic kidney disease?
What are the challenges and strategies in the diagnosis, treatment, and prevention of coronary artery disease in patients with chronic kidney disease?
This review emphasizes the complexities and evidence gaps in managing coronary artery disease among patients with chronic kidney disease.
Coronary artery disease is highly prevalent in patients with chronic kidney disease. The concomitant renal disease often poses a major challenge in decision making as symptoms, cardiac biomarkers and noninvasive studies for evaluation of myocardial ischemia have different sensitivity and specificity thresholds in this specific population. Moreover, the effectiveness and safety of intervention and medical treatment in those patients is of great doubt as most clinical studies exclude patients with advance CKD. In the present paper, we discuss and review the literature in the diagnosis, treatment and prevention of CAD in the acute and chronic setting, in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Skalsky et al. (2022) conducted a review in Coronary artery disease and chronic kidney disease. This review discusses the diagnosis, treatment, and prevention of coronary artery disease in patients with chronic kidney disease, highlighting the exclusion of advanced CKD patients from most trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: